ID

40510

Descripción

A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS); ODM derived from: https://clinicaltrials.gov/show/NCT01230827

Link

https://clinicaltrials.gov/show/NCT01230827

Palabras clave

Versiones (1)
  1. 28/4/20 28/4/20 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

28 de abril de 2020

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Juvenile Idiopathic Arthritis NCT01230827

Inglés

Eligibility Juvenile Idiopathic Arthritis NCT01230827

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis must have been before the patient's 16th birthday
Descripción

Diagnosis | Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011900
UMLS CUI [2]
C0001779
disease duration of at least 6 months before study entry
Descripción

Disease length

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0872146
must have 5 or more joints with active arthritis
Descripción

Arthritis Joints Count

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0003864
UMLS CUI [1,2]
C0022417
UMLS CUI [1,3]
C0750480
must be taking a stable dose of methotrexate 10-30 mg/meter squared (patients with body surface area [bsa] 1.67 square meter or more must be taking a minimum of 15 mg/week of methotrexate)
Descripción

Methotrexate Dose Stable | Body Surface Area

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0025677
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [2]
C0005902
may take a stable dose of prednisone less than 10 mg/day 4 weeks prior to entry or may take a stable dose of nsaids (non-steroidal anti-inflammatory drugs) 2 weeks prior to entry
Descripción

Prednisone Dose Stable U/day | NSAIDs Dose Stable

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0032952
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
UMLS CUI [1,4]
C0456683
UMLS CUI [2,1]
C0003211
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
must have qualifying laboratory values at the first visit.
Descripción

Laboratory Results Qualifying

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1254595
UMLS CUI [1,2]
C1514624
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
have known allergies, hypersensitivity, or intolerance to golimumab or similar therapeutics
Descripción

Hypersensitivity Golimumab | Intolerance to Golimumab | Hypersensitivity Pharmaceutical Preparations Similar | Intolerance to Pharmaceutical Preparations Similar

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C2353893
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C2353893
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0013227
UMLS CUI [3,3]
C2348205
UMLS CUI [4,1]
C1744706
UMLS CUI [4,2]
C0013227
UMLS CUI [4,3]
C2348205
are pregnant or breast-feeding, or planning a pregnancy or fathering a child within 6 months after the last study agent administration
Descripción

Pregnancy | Breast Feeding | Pregnancy, Planned | Reproduction Planned

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0032992
UMLS CUI [4,1]
C0035150
UMLS CUI [4,2]
C1301732
have initiated dmards and/or immunosuppressive therapy within 4 weeks prior to study initiation
Descripción

Initiation DMARDs | Initiation Therapeutic immunosuppression

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1704686
UMLS CUI [1,2]
C0242708
UMLS CUI [2,1]
C1704686
UMLS CUI [2,2]
C0021079
Volver a la parte superior de la página

Similar models

Eligibility Juvenile Idiopathic Arthritis NCT01230827

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Diagnosis | Age
Item
diagnosis must have been before the patient's 16th birthday
boolean
C0011900 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Disease length
Item
disease duration of at least 6 months before study entry
boolean
C0872146 (UMLS CUI [1])
Arthritis Joints Count
Item
must have 5 or more joints with active arthritis
boolean
C0003864 (UMLS CUI [1,1])
C0022417 (UMLS CUI [1,2])
C0750480 (UMLS CUI [1,3])
Methotrexate Dose Stable | Body Surface Area
Item
must be taking a stable dose of methotrexate 10-30 mg/meter squared (patients with body surface area [bsa] 1.67 square meter or more must be taking a minimum of 15 mg/week of methotrexate)
boolean
C0025677 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0005902 (UMLS CUI [2])
Prednisone Dose Stable U/day | NSAIDs Dose Stable
Item
may take a stable dose of prednisone less than 10 mg/day 4 weeks prior to entry or may take a stable dose of nsaids (non-steroidal anti-inflammatory drugs) 2 weeks prior to entry
boolean
C0032952 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0456683 (UMLS CUI [1,4])
C0003211 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
Laboratory Results Qualifying
Item
must have qualifying laboratory values at the first visit.
boolean
C1254595 (UMLS CUI [1,1])
C1514624 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Golimumab | Intolerance to Golimumab | Hypersensitivity Pharmaceutical Preparations Similar | Intolerance to Pharmaceutical Preparations Similar
Item
have known allergies, hypersensitivity, or intolerance to golimumab or similar therapeutics
boolean
C0020517 (UMLS CUI [1,1])
C2353893 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C2353893 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0013227 (UMLS CUI [3,2])
C2348205 (UMLS CUI [3,3])
C1744706 (UMLS CUI [4,1])
C0013227 (UMLS CUI [4,2])
C2348205 (UMLS CUI [4,3])
Pregnancy | Breast Feeding | Pregnancy, Planned | Reproduction Planned
Item
are pregnant or breast-feeding, or planning a pregnancy or fathering a child within 6 months after the last study agent administration
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032992 (UMLS CUI [3])
C0035150 (UMLS CUI [4,1])
C1301732 (UMLS CUI [4,2])
Initiation DMARDs | Initiation Therapeutic immunosuppression
Item
have initiated dmards and/or immunosuppressive therapy within 4 weeks prior to study initiation
boolean
C1704686 (UMLS CUI [1,1])
C0242708 (UMLS CUI [1,2])
C1704686 (UMLS CUI [2,1])
C0021079 (UMLS CUI [2,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial